Christopher Gibson compensation by year
RECURSION PHARMACEUTICALS Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $269,643 | $485,417 | $497,500 | $560,833 | $600,000 | $680,000 |
| Bonus | $13,000 | $0 | — | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $2,573,043 | $3,478,140 | $3,364,500 | $3,808,302 |
| Option awards | $2,268,661 | $0 | $3,047,682 | $4,328,352 | $4,274,816 | $4,846,699 |
| Non-equity incentive | $20,444 | $175,000 | $185,478 | $224,483 | $241,865 | $256,777 |
| Pension and deferred compensation | $0 | $0 | — | $0 | $0 | $0 |
| All other | $12,700 | $13,174 | $12,200 | $21,400 | $18,405 | $15,731 |
| Total | $2,584,448 | $673,591 | $6,303,703 | $8,613,209 | $8,499,587 | $9,607,508 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RECURSION PHARMACEUTICALS, INC. DEF 14A filed April 30, 2026, accession 0001601830-26-000065, and prior-year filings. Open the filing on EDGAR.
How this page was built: the RECURSION PHARMACEUTICALS, INC. filed document, accession 0001601830-26-000065. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 426,793 | $1,745,583 | — |
| RSU | 187,569 | $767,157 | — |
| RSU | 127,125 | $519,941 | — |
| RSU | 13,011 | $53,215 | — |
| Option | 831,706 | — | $7.25 |
| Option | 361,244 | — | $10.09 |
| Option | 237,301 | — | $8.55 |
| Option | 17,349 | — | $11.40 |
Per the Outstanding Equity Awards at Fiscal Year-End table in RECURSION PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2025 proxy (filed April 30, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-05 | Conversion derivative | 10b5-1 | 40,000 | $0.00 | 4,263,334 |
| 2026-06-05 | Sale | 10b5-1 | 40,000 | $3.62 | 883,735 |
| 2026-06-05 | Conversion | 10b5-1 | 40,000 | $0.00 | 923,735 |
| 2026-05-22 | Sale | 10b5-1 | 40,000 | $3.08 | 883,735 |
| 2026-05-22 | Conversion | 10b5-1 | 40,000 | $0.00 | 923,735 |
| 2026-05-22 | Conversion derivative | 10b5-1 | 40,000 | $0.00 | 4,303,334 |
| 2026-05-15 | Tax withholding | — | 22,821 | $3.04 | 883,735 |
| 2026-05-07 | Conversion derivative | 10b5-1 | 60,000 | $0.00 | 4,343,334 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments RECURSION PHARMACEUTICALS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $680,000 | $3,085,897 | $33,453 | $4,479,350 |
| Involuntary termination without cause | $680,000 | $0 | $33,453 | $713,453 |
Per the Potential Payments Upon Termination or Change in Control table in RECURSION PHARMACEUTICALS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
RECURSION PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Christopher Gibson · this page | Former Chief Executive Officer and President and current Chair of the Board | $9,607,508 |
| Najat Khan | Chief Executive Officer and President | $5,349,065 |
| Ben Taylor | Chief Financial Officer and President of Recursion UK | $1,328,483 |
Board service
RECURSION PHARMACEUTICALS board · FY2022–FY2025How this board is paid
Company policy: RECURSION PHARMACEUTICALS pays directors a $35,000 cash retainer and $112,500 in equity. As stated in RECURSION PHARMACEUTICALS's FY2025 proxy.
Committees
Research and Development · Technology · Corporate Social Responsibility (Chair)
Christopher Gibson's compensation dossier, RECURSION PHARMACEUTICALS
You have read Christopher Gibson's totals and holdings. The dossier adds each equity grant RECURSION PHARMACEUTICALS disclosed for Christopher Gibson and RECURSION PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full RECURSION PHARMACEUTICALS compensation record
free company briefThis page is one person within RECURSION PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the RECURSION PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order RECURSION PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RECURSION PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order RXRX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.